BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486-504. [PMID: 26409317 DOI: 10.1016/j.jhep.2015.09.011] [Cited by in Crossref: 297] [Cited by in F6Publishing: 280] [Article Influence: 42.4] [Reference Citation Analysis]
Number Citing Articles
1 Vijgen L, Thys K, Vandebosch A, Van Remoortere P, Verloes R, De Meyer S. Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845. Virol J 2017;14:101. [PMID: 28569206 DOI: 10.1186/s12985-017-0760-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Deng H, Deng X, Liu Y, Xu Y, Lan Y, Gao M, Xu M, Gao H, Wu X, Liao B, Chen W, Zhao M, Hu F, Wang Z. Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China. J Med Virol 2018;90:1246-56. [PMID: 29574921 DOI: 10.1002/jmv.25078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huang Y, Li MH, Hou M, Xie Y. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary Pancreat Dis Int 2017;16:470-9. [PMID: 28992878 DOI: 10.1016/S1499-3872(17)60044-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Tisthammer KH, Dong W, Joy JB, Pennings PS. Comparative Analysis of Within-Host Mutation Patterns and Diversity of Hepatitis C Virus Subtypes 1a, 1b, and 3a. Viruses 2021;13:511. [PMID: 33808782 DOI: 10.3390/v13030511] [Reference Citation Analysis]
5 Forns X, Sarrazin C. Treatment of chronic hepatitis C. J Hepatol 2018;69:544-6. [PMID: 29891100 DOI: 10.1016/j.jhep.2018.04.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, Busch H, Schmutz G, Wehmeyer MH, Boesecke C. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). Clin Infect Dis. 2016;63:1320-1324. [PMID: 27535952 DOI: 10.1093/cid/ciw567] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
7 Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res 2018;248:53-62. [PMID: 29477639 DOI: 10.1016/j.virusres.2018.02.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 20.5] [Reference Citation Analysis]
8 von Massow G, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, Macià MD, Escarda A, Esteban JI, Quer J. Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype. Infect Drug Resist 2019;12:947-55. [PMID: 31118701 DOI: 10.2147/IDR.S195441] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Forton DM. How much of a problem is resistance in treating hepatitis C? Curr Opin Infect Dis 2016;29:625-31. [PMID: 27673712 DOI: 10.1097/QCO.0000000000000319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Perpiñán E, Caro-Pérez N, García-González N, Gregori J, González P, Bartres C, Soria ME, Perales C, Lens S, Mariño Z, Londoño MC, Ariza X, Koutsoudakis G, Quer J, González-Candelas F, Forns X, Pérez-Del-Pulgar S. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. J Viral Hepat 2018;25:1515-25. [PMID: 30141252 DOI: 10.1111/jvh.12986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
11 Rosen HR. "Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research? Hepatology 2017;65:341-9. [PMID: 27640881 DOI: 10.1002/hep.28848] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lawitz EJ, Dvory-Sobol H, Doehle BP, Worth AS, McNally J, Brainard DM, Link JO, Miller MD, Mo H. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016;60:5368-5378. [PMID: 27353271 DOI: 10.1128/aac.00763-16] [Cited by in Crossref: 59] [Cited by in F6Publishing: 21] [Article Influence: 9.8] [Reference Citation Analysis]
13 Jiang X, Lv X, Chang L, Yan Y, Ji H, Sun H, Guo F, Rodgers MA, Yin P, Wang L. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors. Antiviral Res 2020;181:104871. [PMID: 32717286 DOI: 10.1016/j.antiviral.2020.104871] [Reference Citation Analysis]
14 Tavares RCF, de Castro Amaral Feldner AC, Pinho JRR, de Mello Malta F, Carvalho-Filho RJ, Santana RAF, de Castro VFD, Dastoli GTF, Lima JC, Ferraz MLCG. Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus. Infect Drug Resist 2018;11:1993-2000. [PMID: 30464541 DOI: 10.2147/IDR.S169512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Eltahla AA, Rodrigo C, Betz-Stablein B, Grebely J, Applegate T, Luciani F, Schinkel J, Dore GJ, Page K, Bruneau J, Morris MD, Cox AL, Kim AY, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd AR, Bull RA; InC3 Study Group. Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. J Viral Hepat 2017;24:37-42. [PMID: 27666440 DOI: 10.1111/jvh.12615] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
16 Khwaza V, Oyedeji OO, Aderibigbe BA. Antiviral Activities of Oleanolic Acid and Its Analogues. Molecules. 2018;23. [PMID: 30205592 DOI: 10.3390/molecules23092300] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
17 Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. Viruses. 2019;11. [PMID: 30621318 DOI: 10.3390/v11010030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
18 Costa VD, Pellegrini P, Rotman V, Pittella AM, Nunes EP, Lago BV, Lampe E, Mello FCA. Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports. Viruses 2019;11:E1004. [PMID: 31683616 DOI: 10.3390/v11111004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Helal GK, Gad MA, Abd-Ellah MF, Eid MS. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol 2016;88:2170-8. [PMID: 27183377 DOI: 10.1002/jmv.24575] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
20 Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, Kneteman NM, Foung SK. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology 2016;64:1922-33. [PMID: 27641232 DOI: 10.1002/hep.28850] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
21 Esposito I, Marciano S, Trinks J. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:649-57. [PMID: 29855221 DOI: 10.1080/17425255.2018.1483336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
22 Colpitts CC, Baumert TF. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure. Viruses 2016;8:E226. [PMID: 27537906 DOI: 10.3390/v8080226] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
23 Floden EW, Khawaja A, Vopálenský V, Pospíšek M. HCVIVdb: The hepatitis-C IRES variation database. BMC Microbiol 2016;16:187. [PMID: 27527702 DOI: 10.1186/s12866-016-0804-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Zarębska-Michaluk D, Buczyńska I, Simon K, Tudrujek-Zdunek M, Janczewska E, Dybowska D, Sitko M, Dobracka B, Jaroszewicz J, Pabjan P, Klapaczyński J, Laurans Ł, Mazur W, Socha Ł, Tronina O, Parczewski M, Flisiak R. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Can J Gastroenterol Hepatol 2019;2019:4029541. [PMID: 30941326 DOI: 10.1155/2019/4029541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
25 Walker A, Kaiser R, Bartenschlager R, Timm J. Genotypic resistance testing of HCV - is there a clinical need? GMS Infect Dis 2016;4:Doc05. [PMID: 30671319 DOI: 10.3205/id000023] [Reference Citation Analysis]
26 Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study(KULDS) Group. Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis. Hepatol Res. 2017;47:E120-E131. [PMID: 27142311 DOI: 10.1111/hepr.12738] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
27 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Takeda H, Ueda Y, Inuzuka T, Yamashita Y, Osaki Y, Nasu A, Umeda M, Takemura R, Seno H, Sekine A, Marusawa H. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. Sci Rep. 2017;7:45605. [PMID: 28361915 DOI: 10.1038/srep45605] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
29 Pham LV, Jensen SB, Fahnøe U, Pedersen MS, Tang Q, Ghanem L, Ramirez S, Humes D, Serre SB, Schønning K, Bukh J, Gottwein JM. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. Journal of Hepatology 2019;70:388-97. [DOI: 10.1016/j.jhep.2018.10.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
30 Fawsitt CG, Vickerman P, Cooke G, Welton NJ; STOP-HCV Consortium. A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value Health 2019;22:693-703. [PMID: 31198187 DOI: 10.1016/j.jval.2018.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
31 Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol 2019;71:666-72. [PMID: 31203153 DOI: 10.1016/j.jhep.2019.06.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
32 Irekeola AA, Malek NA, Wada Y, Mustaffa N, Muhamad NI, Shueb RH. Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS One 2021;16:e0251673. [PMID: 34014997 DOI: 10.1371/journal.pone.0251673] [Reference Citation Analysis]
33 Kozbial K, Aberle SW, Susser S, Al-zoairy R, Moser S, Stättermayer AF, Maieron A, Gschwantler M, Stauber R, Graziadei I, Zoller H, Beinhardt S, Holzmann H, Munda-steindl P, Hofer H, Sarrazin C, Ferenci P. Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals. Aliment Pharmacol Ther 2017;45:373-5. [DOI: 10.1111/apt.13887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
34 Newsum AM, Ho CK, Lieveld FI, van de Laar TJ, Koekkoek SM, Rebers SP, van der Meer JT, Wensing AM, Boland GJ, Arends JE, van Erpecum KJ, Prins M, Molenkamp R, Schinkel J. The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands. AIDS 2017;31:105-12. [DOI: 10.1097/qad.0000000000001263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
35 Tavares RCF, Feldner ACCA, Pinho JRR, Uehara SNO, Emori CT, Carvalho-Filho RJ, Silva ISS, Santana RAF, de Castro VFD, Castoli GTF, Cristovão CU, Ferraz MLCG. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol 2017;29:754-8. [PMID: 28234637 DOI: 10.1097/MEG.0000000000000866] [Reference Citation Analysis]
36 Akaberi D, Bergfors A, Kjellin M, Kameli N, Lidemalm L, Kolli B, Shafer RW, Palanisamy N, Lennerstrand J. Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach. Infect Ecol Epidemiol 2018;8:1528117. [PMID: 30319736 DOI: 10.1080/20008686.2018.1528117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Jensen SB, Fahnøe U, Pham LV, Serre SBN, Tang Q, Ghanem L, Pedersen MS, Ramirez S, Humes D, Pihl AF, Filskov J, Sølund CS, Dietz J, Fourati S, Pawlotsky JM, Sarrazin C, Weis N, Schønning K, Krarup H, Bukh J, Gottwein JM. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology 2019;70:771-87. [PMID: 30964552 DOI: 10.1002/hep.30647] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
38 Nitta S, Asahina Y, Matsuda M, Yamada N, Sugiyama R, Masaki T, Suzuki R, Kato N, Watanabe M, Wakita T. Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. Sci Rep. 2016;6:34652. [PMID: 27703205 DOI: 10.1038/srep34652] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
39 Lothert K, Offersgaard AF, Pihl AF, Mathiesen CK, Jensen TB, Alzua GP, Fahnøe U, Bukh J, Gottwein JM, Wolff MW. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine. Sci Rep 2020;10:16261. [PMID: 33004836 DOI: 10.1038/s41598-020-72328-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Lagging M, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Westin J; Swedish Consensus Group. Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. Infect Dis (Lond) 2017;49:561-75. [PMID: 28293974 DOI: 10.1080/23744235.2017.1300682] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
41 Mejer N, Fahnøe U, Galli A, Ramirez S, Weiland O, Benfield T, Bukh J. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity. Antimicrob Agents Chemother 2020;64:e01417-20. [PMID: 32928732 DOI: 10.1128/AAC.01417-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape. Gut 2018;67:736-45. [PMID: 28360099 DOI: 10.1136/gutjnl-2016-312577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
43 Castro R, Perazzo H, Grinsztejn B, Veloso VG, Hyde C. Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol. 2015;2015:852968. [PMID: 26693356 DOI: 10.1155/2015/852968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
44 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
45 Ordeig L, Garcia-Cehic D, Gregori J, Soria ME, Nieto-Aponte L, Perales C, Llorens M, Chen Q, Riveiro-Barciela M, Buti M, Esteban R, Esteban JI, Rodriguez-Frias F, Quer J. New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors. J Gen Virol 2018;99:97-102. [PMID: 29239718 DOI: 10.1099/jgv.0.000996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
46 Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe AYM, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. Hepatol Commun 2017;1:379-90. [PMID: 29404466 DOI: 10.1002/hep4.1050] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
47 Loggi E, Vukotic R, Andreone P. Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options. Expert Rev Anti Infect Ther 2018;16:833-8. [PMID: 30336699 DOI: 10.1080/14787210.2018.1538783] [Reference Citation Analysis]
48 Matthew AN, Zephyr J, Nageswara Rao D, Henes M, Kamran W, Kosovrasti K, Hedger AK, Lockbaum GJ, Timm J, Ali A, Kurt Yilmaz N, Schiffer CA. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. mBio 2020;11:e00172-20. [PMID: 32234812 DOI: 10.1128/mBio.00172-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants. Gastroenterology. 2018;154:1435-1448. [PMID: 29274866 DOI: 10.1053/j.gastro.2017.12.015] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
50 Peres-da-Silva A, Antunes D, Quintanilha Torres AL, Caffarena ER, Lampe E. Effects of the Q80K Polymorphism on the Physicochemical Properties of Hepatitis C Virus Subtype 1a NS3 Protease. Viruses 2019;11:E691. [PMID: 31366046 DOI: 10.3390/v11080691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Cento V, Aragri M, Teti E, Polilli E, Bertoli A, Foroghi L, Barbaliscia S, Di Maio VC, Pieri A, Pace Palitti V, Sarmati L, Parruti G, Andreoni M, Perno CF, Ceccherini-Silberstein F. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. J Antimicrob Chemother 2017;72:3420-4. [PMID: 28961921 DOI: 10.1093/jac/dkx302] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
52 Lovelace ES, Polyak SJ. Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection. Viruses 2015;7:6218-32. [PMID: 26633463 DOI: 10.3390/v7122933] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
53 Zhang X, Lv X, Tang S, Mei L, Li Y, Zhang J, Jiang J, Peng Z, Song D. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. European Journal of Medicinal Chemistry 2018;143:1053-65. [DOI: 10.1016/j.ejmech.2017.12.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
54 Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. J Gen Virol 2019;100:1123-31. [PMID: 31199224 DOI: 10.1099/jgv.0.001268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
55 Malta F, Gaspareto KV, Lisboa-Neto G, Carrilho FJ, Mendes-Correa MC, Pinho JRR. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. BMC Infect Dis 2017;17:716. [PMID: 29132303 DOI: 10.1186/s12879-017-2817-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
56 Takeda H, Yamashita T, Ueda Y, Sekine A. Exploring the hepatitis C virus genome using single molecule real-time sequencing. World J Gastroenterol 2019; 25(32): 4661-4672 [PMID: 31528092 DOI: 10.3748/wjg.v25.i32.4661] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
57 Zuckerman A, Chastain CA, Naggie S. Retreatment Options Following HCV Direct Acting Antiviral Failure. Curr Treat Options Infect Dis 2017;9:389-402. [PMID: 29242710 DOI: 10.1007/s40506-017-0136-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
58 Chen J, Zhang X, Luo H, Wu C, Yu M, Liu D, Xi H, Zhou Y, An Y, Xu X. Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens. Oncotarget 2017;8:90916-24. [PMID: 29207613 DOI: 10.18632/oncotarget.18701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
59 Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterol J 2018;6:225-37. [PMID: 29511552 DOI: 10.1177/2050640617717158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
60 Domínguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol. 2001;65:688-693. [PMID: 11745932 DOI: 10.3109/23744235.2015.1113438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
61 Zhuang J, Yin J, Lv S, Wang B, Mu Y. Advanced "lab-on-a-chip" to detect viruses - Current challenges and future perspectives. Biosens Bioelectron 2020;163:112291. [PMID: 32421630 DOI: 10.1016/j.bios.2020.112291] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 16.5] [Reference Citation Analysis]
62 Hanafy AS, Soliman S, Abd-Elsalam S. Rescue therapy for chronic hepatitis C virus infection after repeated treatment failures: Impact on disease progression and risk of hepatocellular carcinoma. Hepatol Res 2019;49:377-84. [PMID: 30570817 DOI: 10.1111/hepr.13303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
63 Sarrazin C, Zimmermann T, Berg T, Hinrichsen H, Mauss S, Wedemeyer H, Zeuzem S; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)., Deutsche Gesellschaft für Pathologie e. V. (DGP) und Bundesverband Deutscher Pathologen (BDP)., Deutsche Leberstiftung., Gesellschaft für Virologie e. V. (GfV)., Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE)., Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH)., Schweizerische Gesellschaft für Gastroenterologie (SGG)., Deutsche Transplantationsgesellschaft e. V. (DTG)., Deutsche Leberhilfe e. V., Deutsche Gesellschaft für Infektiologie e. V. (DGI)., Deutsche Gesellschaft für Suchtmedizin e. V. (DGS)., Deutsche AIDS-Gesellschaft e. V. (DAIG)., Deutsche Arbeitsgemeinschaft niedergelassener Ärzte für die Versorgung HIV-Infizierter (DAGNÄ)., Robert Koch-Institut (RKI)., Collaborators:. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. Z Gastroenterol 2020;58:1110-31. [PMID: 33197953 DOI: 10.1055/a-1226-0241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
64 Caudai C, Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Rossetti B, Almi P, De Luca A, Zazzi M. Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect 2018;24:308.e5-8. [PMID: 28811242 DOI: 10.1016/j.cmi.2017.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
65 Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs 2017;77:131-44. [PMID: 28074358 DOI: 10.1007/s40265-016-0685-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
66 Mangia A, Losappio R, Cenderello G, Potenza D, Mazzola M, De Stefano G, Terreni N, Copetti M, Minerva N, Piazzola V, Bacca D, Palmieri V, Sogari F, Santoro R. Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. PLoS One 2018;13:e0200568. [PMID: 30063745 DOI: 10.1371/journal.pone.0200568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
67 Nieto-Aponte L, Quer J, Ruiz-Ripa A, Tabernero D, Gonzalez C, Gregori J, Vila M, Asensio M, Garcia-Cehic D, Ruiz G, Chen Q, Ordeig L, Llorens M, Saez M, Esteban JI, Esteban R, Buti M, Pumarola T, Rodriguez-Frias F. Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. J Clin Microbiol 2017;55:504-9. [PMID: 27927921 DOI: 10.1128/JCM.01960-16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
68 Weisberg IS, Jacobson IM. Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician. Clin Liver Dis 2017;21:659-72. [PMID: 28987254 DOI: 10.1016/j.cld.2017.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
69 Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol 2016;26:408-34. [PMID: 27401933 DOI: 10.1002/rmv.1895] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
70 Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Med Clin North Am 2016;100:827-50. [PMID: 27235617 DOI: 10.1016/j.mcna.2016.03.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
71 Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6:20310. [PMID: 26842909 DOI: 10.1038/srep20310] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 9.7] [Reference Citation Analysis]
72 Knops E, Schübel N, Heger E, Neumann-Fraune M, Kaiser R, Inden S, Kalaghatgi P, Sierra S. HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy. Clin Gastroenterol Hepatol 2017;15:307-9. [PMID: 27670383 DOI: 10.1016/j.cgh.2016.09.139] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
73 Naguib GG, Michael TG, Elshazly Y, Wahdan MM, Mostafa A, Ahmed OA, Dabbous H, Aly HIS, Shaker MK, Elbaz HS, El-Serafy M, Doss W, Abd-Elsalam S, El-Sayed MH. The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. Virusdisease 2021;32:582-8. [PMID: 34631983 DOI: 10.1007/s13337-021-00712-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Huang W, Wang M, Gong Q, Yu D, Chen P, Lin J, Han Y, Su Y, Qu L, Zhang X. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection. Microb Drug Resist. 2019;. [PMID: 30702389 DOI: 10.1089/mdr.2018.0360] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
75 Craxì A, Perno CF, Viganò M, Ceccherini-silberstein F, Petta S, Aghemo A, Alberti A, Andreone P, Andreoni M, Bonora S, Brunetto MR, Bruno S, Caporaso N, Chirianni A, Ciancio A, Degasperi E, Di Perri G, Fagiuoli S, Ferrari C, Gaeta GB, Pellicelli A, Puoti M, Raimondo G, Taliani G, Villa E, Zignego AL. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016;48:995-1005. [DOI: 10.1016/j.dld.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
76 Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr. 2016;28:93-100. [PMID: 26709684 DOI: 10.1097/mop.0000000000000313] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
77 Sølund C, Andersen ES, Mössner B, Laursen AL, Røge BT, Kjær MS, Gerstoft J, Christensen PB, Pedersen MS, Schønning K, Fahnøe U, Bukh J, Weis N. Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study. Eur J Gastroenterol Hepatol 2018;30:1177-86. [PMID: 29994874 DOI: 10.1097/MEG.0000000000001192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
78 Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni C, Paolucci S, Babudieri S, Siciliano M, Pasquazzi C, Ciancio A, Perno C, Ceccherini-silberstein F, Micheli V, Troshina Y, Biliotti E, Milana M, Melis M, Teti E, Lambiase L, Menzaghi B, Nicolini L, Marenco S, Di Maio V, Aragri M, Pecchioli A, Bertoli A, Sarrecchia C, Macera M, Coppola N, Puoti M, Romagnoli D, Pellicelli A, Bonora S, Novati S, Baldanti F, Ghisetti V, Andreoni M, Taliani G, Rizzardini G, Angelico M. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. Clinical Microbiology and Infection 2017;23:777.e1-4. [DOI: 10.1016/j.cmi.2017.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
79 Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Adinolfi LE, Claar E, Precone D, Stornaiuolo G, Stanzione M, Ascione T, Caroprese M, Zampino R, Parrilli G, Gentile I, Brancaccio G, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna A, Santoro R, Gaeta GB, Coppola N. Virological patterns of HCV patients with failure to interferon-free regimens. J Med Virol. 2018;90:942-950. [PMID: 29315640 DOI: 10.1002/jmv.25022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
80 Wyles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70:1019-1023. [PMID: 30857780 DOI: 10.1016/j.jhep.2019.01.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
81 Zhang Y, Jiang X, Zhao Y, Xu Y. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis. J Viral Hepat 2021;28:177-85. [PMID: 32961624 DOI: 10.1111/jvh.13409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
82 Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. Visc Med. 2019;35:161-170. [PMID: 31367613 DOI: 10.1159/000500963] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
83 Perales C. Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance. Int J Antimicrob Agents 2020;56:105562. [PMID: 30315919 DOI: 10.1016/j.ijantimicag.2018.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
84 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
85 Domingo E, de Ávila AI, Gallego I, Sheldon J, Perales C. Viral fitness: history and relevance for viral pathogenesis and antiviral interventions. Pathog Dis 2019;77:ftz021. [PMID: 30980658 DOI: 10.1093/femspd/ftz021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
86 Llerena S, Cabezas J, Iruzubieta P, Crespo J. Resistance to hepatitis C virus. Implications and therapeutic options. Gastroenterol Hepatol 2017;40:484-94. [PMID: 28647053 DOI: 10.1016/j.gastrohep.2017.04.007] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? J Hepatol 2018;68:597-600. [PMID: 28939133 DOI: 10.1016/j.jhep.2017.09.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
88 Orr C, Xu W, Masur H, Kottilil S, Meissner EG. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis 2020;20:929. [PMID: 33276734 DOI: 10.1186/s12879-020-05657-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Carrion AF, Martin P. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C. Expert Opinion on Drug Safety 2016;15:883-90. [DOI: 10.1080/14740338.2016.1179278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
90 Trucchi C, Orsi A, Alicino C, Sticchi L, Icardi G, Ansaldi F. State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res 2016;2016:1412840. [PMID: 27843956 DOI: 10.1155/2016/1412840] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
91 Lagging M, Wejstål R, Duberg AS, Aleman S, Weiland O, Westin J; ; for the Swedish Consensus Group. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infect Dis (Lond) 2018;50:569-83. [PMID: 29495923 DOI: 10.1080/23744235.2018.1445281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
92 Rodriguez-frias F, Nieto-aponte L, Gregori J, Garcia-cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, Vargas V, Castells L, Viladomiu L, Genesca J, Minguez B, Augustin S, Riveiro-barciela M, Carbonell J, Perales C, Soria M, Asensio M, Llorens M, Ordeig L, Godoy C, Buti M, Esteban R, Pumarola T, Esteban J, Quer J. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection 2017;23:775.e1-6. [DOI: 10.1016/j.cmi.2017.02.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
93 Milazzo L, Magni C, Niero F, Schiavini M, Lai A, Cento V, Binda F, Antinori S, Sollima S. Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience. Eur J Gastroenterol Hepatol 2017;29:1231-4. [PMID: 28877086 DOI: 10.1097/MEG.0000000000000965] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
94 de Torres Santos AP, Martins Silva VC, Mendes-Corrêa MC, Lemos MF, de Mello Malta F, Santana RAF, Dastoli GTF, de Castro VFD, Pinho JRR, Moreira RC. Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil. Infect Drug Resist 2021;14:723-30. [PMID: 33658809 DOI: 10.2147/IDR.S247071] [Reference Citation Analysis]
95 Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Aleman S, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scand J Gastroenterol 2019;54:1042-50. [PMID: 31424972 DOI: 10.1080/00365521.2019.1652846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
96 Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016;22:826-32. [PMID: 27592089 DOI: 10.1016/j.cmi.2016.08.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
97 Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus. Rev Inst Med Trop Sao Paulo 2017;59:e67. [PMID: 29116287 DOI: 10.1590/S1678-9946201759067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Nguyen D, Smith D, Vaughan-jackson A, Magri A, Barnes E, Simmonds P. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. Journal of Hepatology 2020;73:794-9. [DOI: 10.1016/j.jhep.2020.05.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
99 Raja R, Pareek A, Newar K, Dixit NM. Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs. PLoS Pathog 2019;15:e1007701. [PMID: 30934020 DOI: 10.1371/journal.ppat.1007701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
100 Klimova EA, Burnevich EZ, Chulanov VP, Gusev DA, Znoyko OO, Batskikh SN, Kizlo SN, Mamonova NA, Tarkhova EP, Krasavina EN, Samsonov MY, Yushchuk ND. [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C]. Ter Arkh 2019;91:67-74. [PMID: 32598756 DOI: 10.26442/00403660.2019.08.000384] [Reference Citation Analysis]
101 Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. J Gastroenterol 2019;54:916-27. [PMID: 30903385 DOI: 10.1007/s00535-019-01575-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
102 Tamaki S, Shibata T, Hunt T, Gerhardt B, Yamada H, Pai SM. Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects. Clin Pharmacol Drug Dev 2019;8:371-84. [PMID: 30779479 DOI: 10.1002/cpdd.656] [Reference Citation Analysis]
103 Zając M, Muszalska I, Sobczak A, Dadej A, Tomczak S, Jelińska A. Hepatitis C - New drugs and treatment prospects. Eur J Med Chem 2019;165:225-49. [PMID: 30685524 DOI: 10.1016/j.ejmech.2019.01.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
104 Real LM, Macías J, Pérez AB, Merino D, Granados R, Morano L, Delgado M, Ríos MJ, Galera C, Deltoro MG, Merchante N, García F, Pineda JA. Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. Sci Rep 2018;8:14905. [PMID: 30297726 DOI: 10.1038/s41598-018-33367-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
105 Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat 2018;37:17-39. [PMID: 29525636 DOI: 10.1016/j.drup.2018.01.004] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 24.5] [Reference Citation Analysis]
106 Kumada H, Suzuki F, Kamiya N, Orihashi M, Nakayasu Y, Yamada I. Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients. Hepatol Res 2017;47:514-21. [PMID: 27062488 DOI: 10.1111/hepr.12722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
107 Bradley-Stewart A, Goldstein E, MacLean A, Gunson R. Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland. J Clin Virol 2018;101:44-6. [PMID: 29414187 DOI: 10.1016/j.jcv.2018.01.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
108 von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2018;47:1288-1295. [PMID: 29536554 DOI: 10.1111/apt.14592] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
109 Moreira RC, de Torres Santos AP, Lisboa-Neto G, Mendes-Corrêa MCJ, Lemos MF, Malta FM, Santana RAF, Dastoli GTF, de Castro VFD, Pinho JRR. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state. Arch Virol 2018;163:2757-64. [PMID: 29961118 DOI: 10.1007/s00705-018-3920-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
110 Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opin Investig Drugs 2018;27:243-50. [PMID: 29271672 DOI: 10.1080/13543784.2018.1420780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
111 Singh AD, Maitra S, Singh N, Tyagi P, Ashraf A, Kumar R, Shalimar. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther 2020;51:490-504. [PMID: 31943236 DOI: 10.1111/apt.15633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
112 Newsum AM, Molenkamp R, van der Meer JT, Rebers SP, Prins M, van der Valk M, Schinkel J. Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission. J Hepatol 2018;69:968-70. [PMID: 30227918 DOI: 10.1016/j.jhep.2018.06.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
113 Quer J, Rodríguez-Frias F, Gregori J, Tabernero D, Soria ME, García-Cehic D, Homs M, Bosch A, Pintó RM, Esteban JI, Domingo E, Perales C. Deep sequencing in the management of hepatitis virus infections. Virus Res 2017;239:115-25. [PMID: 28040474 DOI: 10.1016/j.virusres.2016.12.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
114 Amer F, Yousif MM, Hammad NM, Garcia-Cehic D, Gregori J, Rando-Segura A, Nieto-Aponte L, Esteban JI, Rodriguez-Frias F, Quer J. Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment. Infect Drug Resist 2019;12:2799-807. [PMID: 31571936 DOI: 10.2147/IDR.S214735] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
115 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194. [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001] [Cited by in Crossref: 712] [Cited by in F6Publishing: 649] [Article Influence: 118.7] [Reference Citation Analysis]
116 Pérez AB, Chueca N, García-deltoro M, Martínez-sapiña AM, Lara-pérez MM, García-bujalance S, Aldámiz-echevarría T, Vera-méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-arboledas JC, Poyato A, Téllez F, Rivero-juárez A, Merino D, Vivancos-gallego MJ, Rosales-zábal JM, García F, Ocete MD, Simón MÁ, Rincón P, Reus S, De la Iglesia A, García-arata I, Jiménez M, Jiménez F, Hernández-quero J, Galera C, Balghata MO, Primo J, Masiá M, Espinosa N, Delgado M, von-Wichmann MÁ, Collado A, Santos J, Mínguez C, Díaz-flores F, Fernández E, Bernal E, De Juan J, Antón JJ, Vélez M, Aguilera A, Navarro D, Arenas JI, Fernández C, Espinosa MD, Ríos MJ, Alonso R, Hidalgo C, Hernández R, Téllez MJ, Rodríguez FJ, Antequera P, Delgado C, Martín P, Crespo J, Becerril B, Pérez Ó, García-herola A, Montero J, Freyre C, Grau C. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. Journal of Hepatology 2019;71:876-88. [DOI: 10.1016/j.jhep.2019.06.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
117 Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O'rear JJ, Naeger LK. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. Hepatology 2018;67:2430-48. [DOI: 10.1002/hep.29693] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
118 Li Z, Zhang Y, Liu Y, Shao X, Luo Q, Cai Q, Zhao Z. Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China. Medicine (Baltimore) 2017;96:e6830. [PMID: 28489763 DOI: 10.1097/MD.0000000000006830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
119 Czarnota A, Offersgaard A, Pihl AF, Prentoe J, Bukh J, Gottwein JM, Bieńkowska-Szewczyk K, Grzyb K. Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. Vaccines (Basel) 2020;8:E294. [PMID: 32532076 DOI: 10.3390/vaccines8020294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
120 Singer JB, Thomson EC, McLauchlan J, Hughes J, Gifford RJ. GLUE: a flexible software system for virus sequence data. BMC Bioinformatics 2018;19:532. [PMID: 30563445 DOI: 10.1186/s12859-018-2459-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
121 Rathi S, Dhiman RK. Hepatobiliary Quiz Answers-17 (2016). J Clin Exp Hepatol 2016;6:73-6. [PMID: 27194902 DOI: 10.1016/j.jceh.2016.03.005] [Reference Citation Analysis]
122 Tsai P, Lin C, Sun H, Lee J, Chang T, Young K. Viral dynamics of persistent hepatitis C virus infection in high-sensitive reporter cells resemble patient's viremia. Journal of Microbiology, Immunology and Infection 2018;51:446-55. [DOI: 10.1016/j.jmii.2016.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
123 Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69:1178-1187. [PMID: 30006068 DOI: 10.1016/j.jhep.2018.07.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
124 Hu C, Yuan G, Liu J, Huang H, Ren Y, Li Y, Chen X, Li W, Wu T, Deng H, Peng Y, Zhang YY, Zhou Y. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China. Can J Gastroenterol Hepatol 2018;2018:3908767. [PMID: 30538973 DOI: 10.1155/2018/3908767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
125 Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease. Liver Int 2017;37:1304-13. [PMID: 28135777 DOI: 10.1111/liv.13376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
126 Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer KH, Graf C, Discher T, Trauth J, Schattenberg JM, Piecha F, Mauss S, Niederau C, Müller T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. Liver Int 2020. [PMID: 32640072 DOI: 10.1111/liv.14591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Witteveldt J, Martin-Gans M, Simmonds P. Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing. Antimicrob Agents Chemother 2016;60:2981-92. [PMID: 26953209 DOI: 10.1128/AAC.02932-15] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
128 Ludmerer SW, Hirano T, Black S, Howe AY, Chang W, Takase A, Nakamura K, Tanaka Y, Kumada H, Hayashi N, Nickle D. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials. Antiviral Res 2016;130:118-29. [PMID: 26947564 DOI: 10.1016/j.antiviral.2016.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
129 Hlaing NKT, Nangia G, Tun KT, Lin S, Maung MZ, Myint KT, Kyaw AMM, Maung ST, Sein Win S, Bwa AH, Loza BL, Win KM, Reddy KR. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar. J Viral Hepat 2019;26:1186-99. [PMID: 31104344 DOI: 10.1111/jvh.13133] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
130 Plissonnier ML, Lahlali T, Michelet M, Lebossé F, Cottarel J, Beer M, Neveu G, Durantel D, Bartosch B, Accardi R, Clément S, Paradisi A, Devouassoux-Shisheboran M, Einav S, Mehlen P, Zoulim F, Parent R. Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus. PLoS Biol 2016;14:e1002421. [PMID: 27031829 DOI: 10.1371/journal.pbio.1002421] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
131 Liu F, Shimakami T, Murai K, Shirasaki T, Funaki M, Honda M, Murakami S, Yi M, Tang H, Kaneko S. Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems. Sci Rep 2016;6:30939. [PMID: 27484655 DOI: 10.1038/srep30939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
132 Jiménez-Pérez M, González-Grande R, España Contreras P, Pinazo Martínez I, de la Cruz Lombardo J, Olmedo Martín R. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. World J Gastroenterol 2016; 22(29): 6573-6581 [PMID: 27547001 DOI: 10.3748/wjg.v22.i29.6573] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
133 Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 2016;151:70-86. [PMID: 27080301 DOI: 10.1053/j.gastro.2016.04.003] [Cited by in Crossref: 368] [Cited by in F6Publishing: 341] [Article Influence: 61.3] [Reference Citation Analysis]
134 Borgia G, Maraolo AE, Buonomo AR, Scotto R, Gentile I. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opin Investig Drugs 2016;25:1209-14. [PMID: 27537604 DOI: 10.1080/13543784.2016.1225036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
135 Raj VS, Hundie GB, Schürch AC, Smits SL, Pas SD, Le Pogam S, Janssen HLA, de Knegt RJ, Osterhaus ADME, Najera I, Boucher CA, Haagmans BL. Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients. Sci Rep 2017;7:4688. [PMID: 28680115 DOI: 10.1038/s41598-017-04931-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
136 Alhaddad O, Wahb A, Sabry A, Khalil F, Elsabaawy D, Elshazly H, Shebl N, Rady M, Elsabaawy M. Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C. Expert Rev Anti Infect Ther 2020;18:817-22. [PMID: 32397842 DOI: 10.1080/14787210.2020.1758557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Hinrichsen H, Stoehr A, Cornberg M, Klinker H, Heyne R, John C, Simon KG, Guenther V, Martin K, Witte V, Zeuzem S. Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry. Eur J Gastroenterol Hepatol 2021;33:415-23. [PMID: 32345848 DOI: 10.1097/MEG.0000000000001759] [Reference Citation Analysis]
138 Li DK, Chung RT. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. In: Law M, editor. Hepatitis C Virus Protocols. New York: Springer; 2019. pp. 3-32. [DOI: 10.1007/978-1-4939-8976-8_1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
139 Howe AYM, Ceccherini-Silberstein F, Dietz J, Popping S, Grebely J, Rodrigo C, Lennerstrand J, Douglas MW, Parczewsk M, Harrigan PR, Pawlotsky JM, Garcia F, Collaborators S. SHARED: An International Collaboration to Unravel Hepatitis C Resistance. Viruses 2021;13:1580. [PMID: 34452444 DOI: 10.3390/v13081580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Rahimi P, Sharafi H, Bahramali G, SajadianFard F, Asadi NS, Alavian SM, Iranpur Mobarakeh V, Moravej SZ. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. Front Microbiol 2020;11:617375. [PMID: 33584581 DOI: 10.3389/fmicb.2020.617375] [Reference Citation Analysis]
141 Yang S, Xing H, Feng S, Ju W, Liu S, Wang X, Ou W, Cheng J, Pan CQ. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C. Arch Virol 2018;163:467-73. [PMID: 29143142 DOI: 10.1007/s00705-017-3640-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
142 Zhou K, Liang Z, Wang C, Hu F, Ning C, Lan Y, Tang X, Tucker JD, Cai W. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China. PLoS One 2016;11:e0157438. [PMID: 27341031 DOI: 10.1371/journal.pone.0157438] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
143 Asante-Appiah E, Liu R, Curry S, McMonagle P, Agrawal S, Carr D, Rokosz L, Lahser F, Bystol K, Chase R, Black S, Ferrari E, Ingravallo P, Tong L, Yu W, Kozlowski J. In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. Antimicrob Agents Chemother 2018;62:e01280-18. [PMID: 30150466 DOI: 10.1128/AAC.01280-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Madsen LW, Christensen PB, Fahnøe U, Pedersen MS, Bukh J, Øvrehus A. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C. Liver Int 2021. [PMID: 34154034 DOI: 10.1111/liv.14991] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Li HC, Yang CH, Lo SY. Hepatitis C Viral Replication Complex. Viruses 2021;13:520. [PMID: 33809897 DOI: 10.3390/v13030520] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Chen Q, Perales C, Soria ME, García-Cehic D, Gregori J, Rodríguez-Frías F, Buti M, Crespo J, Calleja JL, Tabernero D, Vila M, Lázaro F, Rando-Segura A, Nieto-Aponte L, Llorens-Revull M, Cortese MF, Fernandez-Alonso I, Castellote J, Niubó J, Imaz A, Xiol X, Castells L, Riveiro-Barciela M, Llaneras J, Navarro J, Vargas-Blasco V, Augustin S, Conde I, Rubín Á, Prieto M, Torras X, Margall N, Forns X, Mariño Z, Lens S, Bonacci M, Pérez-Del-Pulgar S, Londoño MC, García-Buey ML, Sanz-Cameno P, Morillas R, Martró E, Saludes V, Masnou-Ridaura H, Salmerón J, Quíles R, Carrión JA, Forné M, Rosinach M, Fernández I, García-Samaniego J, Madejón A, Castillo-Grau P, López-Núñez C, Ferri MJ, Durández R, Sáez-Royuela F, Diago M, Gimeno C, Medina R, Buenestado J, Bernet A, Turnes J, Trigo-Daporta M, Hernández-Guerra M, Delgado-Blanco M, Cañizares A, Arenas JI, Gomez-Alonso MJ, Rodríguez M, Deig E, Olivé G, Río OD, Cabezas J, Quiñones I, Roget M, Montoliu S, García-Costa J, Force L, Blanch S, Miralbés M, López-de-Goicoechea MJ, García-Flores A, Saumoy M, Casanovas T, Baliellas C, Gilabert P, Martin-Cardona A, Roca R, Barenys M, Villaverde J, Salord S, Camps B, Silvan di Yacovo M, Ocaña I, Sauleda S, Bes M, Carbonell J, Vargas-Accarino E, Ruzo SP, Guerrero-Murillo M, Von Massow G, Costafreda MI, López RM, González-Moreno L, Real Y, Acero-Fernández D, Viroles S, Pamplona X, Cairó M, Ocete MD, Macías-Sánchez JF, Estébanez A, Quer JC, Mena-de-Cea Á, Otero A, Castro-Iglesias Á, Suárez F, Vázquez Á, Vieito D, López-Calvo S, Vázquez-Rodríguez P, Martínez-Cerezo FJ, Rodríguez R, Macenlle R, Cachero A, Mereish G, Mora-Moruny C, Fábregas S, Sacristán B, Albillos A, Sánchez-Ruano JJ, Baluja-Pino R, Fernández-Fernández J, González-Portela C, García-Martin C, Sánchez-Antolín G, Andrade RJ, Simón MA, Pascasio JM, Romero-Gómez M, Antonio Del-Campo J, Domingo E, Esteban R, Esteban JI, Quer J. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res 2020;174:104694. [PMID: 31857134 DOI: 10.1016/j.antiviral.2019.104694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
147 Humes D, Ramirez S, Jensen TB, Li YP, Gottwein JM, Bukh J. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. Virology 2018;522:177-92. [PMID: 30032031 DOI: 10.1016/j.virol.2018.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
148 Gane EJ, Stedman CA, Schwabe C, Vijgen L, Chanda S, Kakuda TN, Fry J, Blatt LM, McClure MW. Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis. Hepatology 2018;68:2145-57. [PMID: 30070722 DOI: 10.1002/hep.30126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
149 Ahmed A, Felmlee DJ. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 2015;7:6716-29. [PMID: 26694454 DOI: 10.3390/v7122968] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
150 Shah S, Chougule MB, Kotha AK, Kashikar R, Godugu C, Raghuvanshi RS, Singh SB, Srivastava S. Nanomedicine based approaches for combating viral infections. J Control Release 2021;338:80-104. [PMID: 34375690 DOI: 10.1016/j.jconrel.2021.08.011] [Reference Citation Analysis]
151 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
152 Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators., Spanish GEHEP-004 Collaborators., Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol 2021;74:801-10. [PMID: 33220331 DOI: 10.1016/j.jhep.2020.11.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
153 Jalota A, Lindner BK, Thomas B, Lerma EV. Hepatitis C and Treatment in Patients with Chronic Kidney Disease. Dis Mon 2021;67:101017. [PMID: 32553421 DOI: 10.1016/j.disamonth.2020.101017] [Reference Citation Analysis]
154 Zoulim F, Moreno C, Lee SS, Buggisch P, Horban A, Lawitz E, Corbett C, Lenz O, Fevery B, Verbinnen T, Shukla U, Jessner W. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection. Virol J 2018;15:26. [PMID: 29378602 DOI: 10.1186/s12985-018-0936-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
155 Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016;12:1197-1209. [PMID: 27384079 DOI: 10.1080/17425255.2016.1209484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
156 Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, Ridolfo A, Gervasoni C, Galli M, Antinori S, Sollima S. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med 2017;18:284-91. [DOI: 10.1111/hiv.12429] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
157 Hull MW, Yoshida EM, Montaner JS. Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Curr Infect Dis Rep 2016;18:22. [PMID: 27357277 DOI: 10.1007/s11908-016-0527-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
158 Martínez AP, Culasso ACA, Pérez PS, Romano V, Campos RH, Ridruejo E, García G, Di Lello FA. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K. Virus Res 2017;240:140-6. [PMID: 28837817 DOI: 10.1016/j.virusres.2017.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
159 Martínez AP, García G, Ridruejo E, Culasso AC, Pérez PS, Pereson MJ, Neukam K, Flichman D, Di Lello FA. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina. J Med Virol 2019;91:1970-8. [PMID: 31273794 DOI: 10.1002/jmv.25536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
160 Bagaglio S, Messina E, Hasson H, Galli A, Uberti-Foppa C, Morsica G. Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions. Viruses 2019;11:E148. [PMID: 30754682 DOI: 10.3390/v11020148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
161 Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. Journal of Hepatology 2021;74:1472-82. [DOI: 10.1016/j.jhep.2021.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
162 Behrendt P, Perin P, Menzel N, Banda D, Pfaender S, Alves MP, Thiel V, Meuleman P, Colpitts CC, Schang LM, Vondran FWR, Anggakusuma, Manns MP, Steinmann E, Pietschmann T. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antiviral Res 2017;147:19-28. [PMID: 28923507 DOI: 10.1016/j.antiviral.2017.09.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
163 Peiffer KH, Vermehren J, Kuhnhenn L, Susser S, Dietz J, Finkelmeier F, Weiler N, Welzel T, Grammatikos G, Zeuzem S, Sarrazin C. Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. J Infect Chemother. 2018;24:524-530. [PMID: 29628383 DOI: 10.1016/j.jiac.2018.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
164 Nageswara Rao D, Zephyr J, Henes M, Chan ET, Matthew AN, Hedger AK, Conway HL, Saeed M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. J Med Chem 2021;64:11972-89. [PMID: 34405680 DOI: 10.1021/acs.jmedchem.1c00554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017;5:Doc08. [PMID: 30671330 DOI: 10.3205/id000034] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
166 Romeo I, Marascio N, Pavia G, Talarico C, Costa G, Alcaro S, Artese A, Torti C, Liberto MC, Focà A. Structural Modeling of New Polymorphism Clusters of HCV Polymerase Isolated from Direct‐Acting Antiviral Naïve Patients: Focus on Dasabuvir and Setrobuvir Binding Affinity. ChemistrySelect 2018;3:6009-17. [DOI: 10.1002/slct.201800649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
167 Wang B, Krüger L, Machnowska P, Eshetu A, Gunsenheimer-Bartmeyer B, Bremer V, Hauser A, Bannert N, Bock CT. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o. Virol J 2019;16:28. [PMID: 30832687 DOI: 10.1186/s12985-019-1135-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
168 Noble CF, Malta F, Lisboa-Neto G, Gomes-Gouvêa MS, Leite AGB, de Castro VFD, Santana RAF, Carrilho FJ, Mendes-Correa MC, Pinho JRR. Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV. Arch Virol 2017;162:165-9. [PMID: 27704215 DOI: 10.1007/s00705-016-3094-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
169 Shah ND, Fried MW. Treatment options of patients with chronic hepatitis C who have failed prior therapy. Clin Liver Dis (Hoboken) 2016;7:40-4. [PMID: 31041026 DOI: 10.1002/cld.532] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Takehara T, Chayama K, Kurosaki M, Yatsuhashi H, Tanaka Y, Hiramatsu N, Sakamoto N, Asahina Y, Nozaki A, Nakano T, Hagiwara Y, Shimizu H, Yoshida H, Huang Y, Biermer M, Vijgen L, Hayashi N. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. J Gastroenterol 2020;55:640-52. [DOI: 10.1007/s00535-020-01672-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Carrasco I, Arias A, Benítez-Gutiérrez L, Lledó G, Requena S, Cuesta M, Cuervas-Mons V, de Mendoza C. Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients. J Med Virol 2018;90:532-6. [PMID: 28990680 DOI: 10.1002/jmv.24971] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
172 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
173 Rusere LN, Matthew AN, Lockbaum GJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants. ACS Med Chem Lett 2018;9:691-6. [PMID: 30034602 DOI: 10.1021/acsmedchemlett.8b00150] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
174 Mesalam AA, Vercauteren K, Meuleman P. Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses 2016;8:E176. [PMID: 27338446 DOI: 10.3390/v8060176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
175 Kozbial K, Al‐zoairy R, Gschwantler M, Stauber R, Hametner S, Laferl H, Strasser M, Hayat‐khayyati A, Datz C, Kramer L, Schaefer B, Maieron A, Graziadei I, Stättermayer AF, Beinhardt S, Munda P, Zoller H, Holzmann H, Aberle SW, Trauner M, Hofer H, Ferenci P. Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy. GastroHep 2019;1:76-83. [DOI: 10.1002/ygh2.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
176 Paolucci S, Piralla A, Novazzi F, Fratini A, Maserati R, Gulminetti R, Novati S, Barbarini G, Sacchi P, Silvestri A, Baldanti F. Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs. Viruses 2020;12:E255. [PMID: 32106574 DOI: 10.3390/v12030255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Fabrizi F, Messa P. Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 2018;11:1135-42. [PMID: 30309263 DOI: 10.1080/17512433.2018.1534202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
178 Fichter M, Piradashvili K, Pietrzak-Nguyen A, Pretsch L, Kuhn G, Strand S, Knuf M, Zepp F, Wurm FR, Mailänder V, Landfester K, Gehring S. Polymeric hepatitis C virus non-structural protein 5A nanocapsules induce intrahepatic antigen-specific immune responses. Biomaterials 2016;108:1-12. [PMID: 27614817 DOI: 10.1016/j.biomaterials.2016.08.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
179 Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J Hepatol. 2017;66:910-918. [PMID: 28108232 DOI: 10.1016/j.jhep.2017.01.007] [Cited by in Crossref: 148] [Cited by in F6Publishing: 138] [Article Influence: 29.6] [Reference Citation Analysis]
180 Soria ME, Gregori J, Chen Q, García-Cehic D, Llorens M, de Ávila AI, Beach NM, Domingo E, Rodríguez-Frías F, Buti M, Esteban R, Esteban JI, Quer J, Perales C. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis 2018;18:446. [PMID: 30176817 DOI: 10.1186/s12879-018-3356-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
181 Sano T, Akuta N, Suzuki F, Kasuya K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H. Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis. Intern Med 2019;58:2657-62. [PMID: 31178495 DOI: 10.2169/internalmedicine.2604-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
182 Sahuc ME, Sahli R, Rivière C, Pène V, Lavie M, Vandeputte A, Brodin P, Rosenberg AR, Dubuisson J, Ksouri R, Rouillé Y, Sahpaz S, Séron K. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. J Virol 2019;93:e02009-18. [PMID: 30842319 DOI: 10.1128/JVI.02009-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
183 Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One 2019;14:e0221231. [PMID: 31469856 DOI: 10.1371/journal.pone.0221231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
184 Malandris K, Kalopitas G, Theocharidou E, Germanidis G. The Role of RASs /RVs in the Current Management of HCV. Viruses 2021;13:2096. [PMID: 34696525 DOI: 10.3390/v13102096] [Reference Citation Analysis]
185 Nitta S, Asahina Y, Kato T, Tsuchiya J, Inoue-Shinomiya E, Sato A, Tsunoda T, Miyoshi M, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Hikita H, Takehara T, Watanabe M. Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. Sci Rep 2019;9:5722. [PMID: 30952914 DOI: 10.1038/s41598-019-42114-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
186 Carter W, Connelly S, Struble K. Reinventing HCV Treatment: Past and Future Perspectives. J Clin Pharmacol. 2017;57:287-296. [PMID: 27654843 DOI: 10.1002/jcph.830] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
187 Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J Med Virol 2017;89:1248-54. [PMID: 28079269 DOI: 10.1002/jmv.24767] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
188 Pérez AB, Chueca N, García F. Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long? Germs 2017;7:40-4. [PMID: 28331841 DOI: 10.18683/germs.2017.1107] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
189 Ji X, Chen J, Zheng G, Huang M, Zhang L, Yi H, Jin J, Jiang J, Peng Z, Li Z. Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N -Acetylgalactosaminyltransferase 1. J Med Chem 2016;59:10268-84. [DOI: 10.1021/acs.jmedchem.6b01301] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
190 Morillas RM, Masnou H, Ardévol M, López D. Role of ribavirin in interferon-free therapy for the treatment of hepatitisC virus. Gastroenterol Hepatol 2017;40:699-708. [PMID: 28823382 DOI: 10.1016/j.gastrohep.2017.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
191 Jimenez-Sousa MÁ, Gutiérrez-Rivas M, Álvaro-Meca A, García-Álvarez M, Harrigan PR, Fedele CG, Briz V, Vázquez-Morón S, Resino S. NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. PLoS One 2016;11:e0163197. [PMID: 27685471 DOI: 10.1371/journal.pone.0163197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
192 Dietz J, Kalinina OV, Vermehren J, Peiffer K, Matschenz K, Buggisch P, Niederau C, Schattenberg JM, Müllhaupt B, Yerly S, Ringelhan M, Schmid RM, Antoni C, Müller T, Schulze zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg CP, Zeuzem S, Welsch C, Sarrazin C; European HCV Resistance Study Group. Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. J Viral Hepat 2020;27:974-86. [DOI: 10.1111/jvh.13322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
193 Pham LV, Ramirez S, Carlsen THR, Li YP, Gottwein JM, Bukh J. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors. Antimicrob Agents Chemother 2017;61:e00037-17. [PMID: 28348150 DOI: 10.1128/AAC.00037-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
194 Berenguer M. Last gasps of the hepatitis C virus dragon: Direct acting antiviral failures and hepatitis C virus-positive donors. Liver Transpl 2016;22:47-51. [PMID: 27465590 DOI: 10.1002/lt.24520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
195 Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist 2017;10:377-92. [PMID: 29184422 DOI: 10.2147/IDR.S146595] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
196 Muller S, Brietzke AP, Dos Santos DC, Jacinto MM, Michalczuk MT, Álvarez-da-Silva MR. The Evaluation of Medication Adherence in Patients Infected With HCV Receiving Protease Inhibitors: A Pilot Study. Gastroenterol Nurs 2019;42:259-68. [PMID: 31145250 DOI: 10.1097/SGA.0000000000000386] [Reference Citation Analysis]
197 Pisaturo M, Starace M, Minichini C, De Pascalis S, Occhiello L, Fraia AD, Messina V, Sangiovanni V, Claar E, Coppola N; CampC Network. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals. Int J Antimicrob Agents 2020;56:106067. [PMID: 32599227 DOI: 10.1016/j.ijantimicag.2020.106067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Liu Z, Mao X, Wu J, Yu K, Yang Q, Suo C, Lu M, Jin L, Zhang T, Chen X. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology 2021;19:1906-1914.e25. [DOI: 10.1016/j.cgh.2019.10.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
199 Kyuregyan KK, Kichatova VS, Karlsen AA, Isaeva OV, Solonin SA, Petkov S, Nielsen M, Isaguliants MG, Mikhailov MI. Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C. Biomedicines 2020;8:E80. [PMID: 32272736 DOI: 10.3390/biomedicines8040080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Bagaglio S, Hasson H, Peano L, Vercesi R, Messina E, Galli A, Foppa CU, Morsica G. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome. Viruses 2020;12:E269. [PMID: 32121164 DOI: 10.3390/v12030269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
201 Martinez MA, Franco S. Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses 2020;13:E41. [PMID: 33383891 DOI: 10.3390/v13010041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
202 Novikov D, Feng JE, Anoushiravani AA, Vigdorchik JM, Lajam CM, Seyler TM, Schwarzkopf R. Undetectable Hepatitis C Viral Load Is Associated With Improved Outcomes Following Total Joint Arthroplasty. J Arthroplasty 2019;34:2890-7. [PMID: 31351854 DOI: 10.1016/j.arth.2019.06.058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
203 Tin K, Soe E, Park J. Management of Direct-Acting Antiviral Failures in Chronic Hepatitis C Infection. Curr Hepatology Rep 2016;15:296-306. [DOI: 10.1007/s11901-016-0326-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
204 Lucas M, Deshpande P, James I, Rauch A, Pfafferott K, Gaylard E, Merani S, Plauzolles A, Lucas A, McDonnell W, Kalams S, Pilkinton M, Chastain C, Barnett L, Prosser A, Mallal S, Fitzmaurice K, Drummer H, Ansari MA, Pedergnana V, Barnes E, John M, Kelleher D, Klenerman P, Gaudieri S. Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome. Sci Rep 2018;8:7224. [PMID: 29740042 DOI: 10.1038/s41598-018-25559-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
205 Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK. Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. Gut Liver 2019;13:549-56. [PMID: 30970433 DOI: 10.5009/gnl18432] [Reference Citation Analysis]
206 Kjellin M, Wesslén T, Löfblad E, Lennerstrand J, Lannergård A. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Ups J Med Sci 2018;123:50-6. [PMID: 29536805 DOI: 10.1080/03009734.2018.1441928] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
207 Walker A, Bergmann M, Camdereli J, Kaiser R, Lübke N, Timm J. A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing. Journal of Clinical Virology 2017;91:42-8. [DOI: 10.1016/j.jcv.2017.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
208 Sayan M, Yıldırım FS, Akhan S, Yıldırım AA, Şirin G, Cabalak M, Demir M, Can S, Ersöz G, Altıntaş E, Ensaroğlu F, Akbulut A, Şener A, Deveci A. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. Int J Infect Dis 2020;95:84-9. [PMID: 32302766 DOI: 10.1016/j.ijid.2020.03.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Pham LV, Ramirez S, Gottwein JM, Fahnøe U, Li YP, Pedersen J, Bukh J. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. Gastroenterology 2018;154:2194-2208.e12. [PMID: 29454794 DOI: 10.1053/j.gastro.2018.02.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
210 Pihl AF, Offersgaard AF, Mathiesen CK, Prentoe J, Fahnøe U, Krarup H, Bukh J, Gottwein JM. High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals. Sci Rep 2018;8:17505. [PMID: 30504788 DOI: 10.1038/s41598-018-35010-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
211 Zuccaro V, Lombardi A, Asperges E, Sacchi P, Bruno R. PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment? Expert Opin Drug Metab Toxicol 2020;16:97-101. [PMID: 32003256 DOI: 10.1080/17425255.2020.1721459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
212 Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Peña JM, Arias A, Barreiro P. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother 2017;18:1235-42. [PMID: 28644739 DOI: 10.1080/14656566.2017.1346609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
213 Zhang Y, Cao Y, Zhang R, Zhang X, Lu H, Wu C, Huo N, Xu X. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients. PLoS One 2016;11:e0165658. [PMID: 27812165 DOI: 10.1371/journal.pone.0165658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
214 Moreno E, Gallego I, Gregori J, Lucía-Sanz A, Soria ME, Castro V, Beach NM, Manrubia S, Quer J, Esteban JI, Rice CM, Gómez J, Gastaminza P, Domingo E, Perales C. Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment. J Virol 2017;91:e02505-16. [PMID: 28275194 DOI: 10.1128/JVI.02505-16] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
215 Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Serikawa M, Aikata H, Ochi H, Ishida Y, Tateno C, Ohdan H, Chayama K. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus. PLoS One 2017;12:e0172412. [PMID: 28253324 DOI: 10.1371/journal.pone.0172412] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
216 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
217 Dvory-Sobol H, Han B, Lu J, Yu M, Beran RK, Cheng G, Martin R, Svarovskaia E, Mo H. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6. J Viral Hepat 2019;26:991-1001. [PMID: 31009123 DOI: 10.1111/jvh.13116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
218 Sun D, Dai M, Shen S, Li C, Yan X. Analysis of naturally occurring resistance-associated variants to NS3/4A protein inhibitors, NS5A protein inhibitors and NS5B polymerase inhibitors in patients with chronic hepatitis C. Gene Expr. 2017;. [PMID: 29221500 DOI: 10.3727/105221617x15100607143377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
219 Okai K, Ichikawa-Tomikawa N, Saito AC, Watabe T, Sugimoto K, Fujita D, Ono C, Fukuhara T, Matsuura Y, Ohira H, Chiba H. A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro. Oncotarget 2018;9:16588-98. [PMID: 29682171 DOI: 10.18632/oncotarget.24742] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
220 Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. Journal of Hepatology 2016;65:S2-S21. [DOI: 10.1016/j.jhep.2016.07.035] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 19.5] [Reference Citation Analysis]
221 Benítez-Gutiérrez L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, Peña JM, Soriano V. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother 2016;17:1215-23. [PMID: 27149603 DOI: 10.1080/14656566.2016.1182156] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
222 Maasoumy B, Höner Zu Siederdissen C. Editorial: retreatment of DAA-failures-no problem at all? Aliment Pharmacol Ther 2018;47:1552-3. [PMID: 29878438 DOI: 10.1111/apt.14650] [Reference Citation Analysis]
223 Tao W, Gan T, Lu J, Zhong J. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. Antiviral Res 2017;139:18-24. [PMID: 28025084 DOI: 10.1016/j.antiviral.2016.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
224 Walker A, Filke S, Lübke N, Obermeier M, Kaiser R, Häussinger D, Timm J, Bock HH. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure. Virol J 2017;14:106. [PMID: 28595606 DOI: 10.1186/s12985-017-0779-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
225 Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O’rear JJ, Harrington PR. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Gastroenterology 2017;152:586-97. [DOI: 10.1053/j.gastro.2016.10.017] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
226 Asante-Appiah E, Ingravallo P, McMonagle P, Bystol K, Xia E, Curry S, Qiu P, Black S, Chase R, Liu R, Lahser F. Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in HCV GT2. Antimicrob Agents Chemother 2019:AAC. [PMID: 31527040 DOI: 10.1128/AAC.01269-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
227 El Kassas M, Alboraie M, El Badry M, Youssef N, Omar H, El Sheemy RY, Al Balakosy A, Ashraf Ahmed Mohamed O, Gamal Naguib Meleak G, Dabbous H, Hassan Ahmed Fouad M, Wifi MN, Zaky S, Tahoon M, El Tahan A, El-Raey F, Ezzat S, Doss W. Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study. Int J Infect Dis 2020;96:367-70. [PMID: 32325275 DOI: 10.1016/j.ijid.2020.04.022] [Reference Citation Analysis]
228 Paolucci S, Novazzi F, Piralla A, Maserati R, Gulminetti R, Novati S, Barbarini G, Sacchi P, Fratini A, Bellotti L, Baldanti F. Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations. Infect Drug Resist 2019;12:1975-84. [PMID: 31372005 DOI: 10.2147/IDR.S205282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Ruggiero T, Burdino E, Calcagno A, Bonora S, Boglione L, Di Perri G, Ghisetti V. HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing. Infection 2016;44:789-92. [PMID: 27522673 DOI: 10.1007/s15010-016-0937-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
230 Vopálenský V, Khawaja A, Rožnovský L, Mrázek J, Mašek T, Pospíšek M. Characterization of Hepatitis C Virus IRES Quasispecies - From the Individual to the Pool. Front Microbiol 2018;9:731. [PMID: 29740402 DOI: 10.3389/fmicb.2018.00731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
231 Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G, Sacchi P, Piralla A, Sassera D, De Marco L, Girello A, Mondelli MU, Baldanti F. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Sci Rep. 2017;7:16017. [PMID: 29167469 DOI: 10.1038/s41598-017-15987-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
232 Morsica G, Vercesi R, Hasson H, Messina E, Uberti-Foppa C, Bagaglio S. Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype. Viruses 2021;13:1486. [PMID: 34452351 DOI: 10.3390/v13081486] [Reference Citation Analysis]
233 Ortega-Prieto AM, Dorner M. The expanding toolbox for hepatitis C virus research. J Viral Hepat 2016;23:320-9. [PMID: 26762605 DOI: 10.1111/jvh.12500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
234 Kumada H, Mochida S, Nakamuta M, Suzuki F, Yagi T, Takasaki R, Okai M, Kamiya N, Okada Y, Hirota S, Orihashi M, Ochi M, Chayama K. Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression. Hepatol Res 2018;48:184-92. [PMID: 28497489 DOI: 10.1111/hepr.12914] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
235 Nguyen T, Akhavan S, Caby F, Bonyhay L, Larrouy L, Gervais A, Lebray P, Poynard T, Calmus Y, Simon A, Valantin MA, Calvez V, Marcelin AG, Todesco E. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. Int J Antimicrob Agents 2019;53:80-3. [PMID: 30236959 DOI: 10.1016/j.ijantimicag.2018.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
236 de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. J Antimicrob Chemother 2020;75:3349-58. [PMID: 32772078 DOI: 10.1093/jac/dkaa304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
237 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
238 Andre-Garnier E, Besse B, Rodallec A, Ribeyrol O, Ferre V, Luco C, Le Guen L, Bourgeois N, Gournay J, Billaud E, Raffi F, Coste-Burel M, Imbert-Marcille BM. An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains. PLoS One 2017;12:e0179562. [PMID: 28727784 DOI: 10.1371/journal.pone.0179562] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
239 de Ávila AI, Gallego I, Soria ME, Gregori J, Quer J, Esteban JI, Rice CM, Domingo E, Perales C. Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. PLoS One 2016;11:e0164691. [PMID: 27755573 DOI: 10.1371/journal.pone.0164691] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
240 Houssel-Debry P, Coilly A, Fougerou-Leurent C, Jezequel C, Duvoux C, De Ledinghen V, Radenne S, Kamar N, Leroy V, Martino VD, D'Alteroche L, Canva V, Conti F, Dumortier J, Montialoux H, Lebray P, Botta-Fridlund D, Tran A, Moreno C, Silvain C, Besch C, Perre P, Francoz C, Abergel A, Habersetzer F, Debette-Gratien M, Cagnot C, Diallo A, Chevaliez S, Rossignol E, Veislinger A, Duclos-Vallee JC, Pageaux GP; the ANRS CO23 CUPILT study group. 12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. Hepatology 2018;68:1277-87. [PMID: 29633389 DOI: 10.1002/hep.29918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
241 Dietz J, Rupp D, Susser S, Vermehren J, Peiffer KH, Filmann N, Bon D, Kuntzen T, Mauss S, Grammatikos G, Perner D, Berkowski C, Herrmann E, Zeuzem S, Bartenschlager R, Sarrazin C. Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS One 2016;11:e0156731. [PMID: 27281344 DOI: 10.1371/journal.pone.0156731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
242 Matsumoto T, Takami T, Sakaida I. Cell transplantation as a non-invasive strategy for treating liver fibrosis. Expert Rev Gastroenterol Hepatol 2016;10:639-48. [PMID: 26691057 DOI: 10.1586/17474124.2016.1134313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
243 Mo H, Hedskog C, Lawitz E, Brainard DM, Yang J, Delaney W, Worth A, Miller MD. Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res 2017;140:151-7. [PMID: 28132867 DOI: 10.1016/j.antiviral.2017.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
244 Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. Gastroenterology 2018;154:976-988.e4. [PMID: 29146520 DOI: 10.1053/j.gastro.2017.11.007] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 16.6] [Reference Citation Analysis]
245 Cornberg M, Petersen J, Schober A, Mauss S, Böker KHW, Link R, Günther R, Serfert Y, Pfeiffer-vornkahl H, Manns MP, Sarrazin C, Hüppe D, Berg T, Niederau C. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2017;45:688-700. [DOI: 10.1111/apt.13925] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
246 Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Soñora M, Cristina J, Moratorio G, Hernández N, Moreno P. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report. BMC Infect Dis 2021;21:387. [PMID: 33902462 DOI: 10.1186/s12879-021-06080-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Chueca N, Rivadulla I, Lovatti R, Reina G, Blanco A, Fernandez-Caballero JA, Cardeñoso L, Rodriguez-Granjer J, Fernandez-Alonso M, Aguilera A, Alvarez M, Galán JC, García F. Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms. PLoS One 2016;11:e0153754. [PMID: 27097040 DOI: 10.1371/journal.pone.0153754] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
248 Ma Y, Frutos-Beltrán E, Kang D, Pannecouque C, De Clercq E, Menéndez-Arias L, Liu X, Zhan P. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev 2021;50:4514-40. [PMID: 33595031 DOI: 10.1039/d0cs01084g] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
249 Ohya K, Imamura M, Teraoka Y, Uchida T, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Abe-Chayama H, Hayes CN, Aikata H, Ishida Y, Tateno C, Song H, Miyayama Y, Hijikata M, Chayama K. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. Biochem Biophys Res Commun 2021;559:78-83. [PMID: 33932902 DOI: 10.1016/j.bbrc.2021.04.062] [Reference Citation Analysis]
250 Martinez MA, Franco S. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. Adv Exp Med Biol 2021;1322:139-57. [PMID: 34258740 DOI: 10.1007/978-981-16-0267-2_6] [Reference Citation Analysis]
251 Itakura J, Kurosaki M, Kakizaki S, Amano K, Nakayama N, Inoue J, Endo T, Marusawa H, Hasebe C, Joko K, Wada S, Akahane T, Koushima Y, Ogawa C, Kanto T, Mizokami M, Izumi N. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. JHEP Rep 2020;2:100138. [PMID: 32817930 DOI: 10.1016/j.jhepr.2020.100138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
252 Soriano V, Benítez-Gutiérrez L, Arias A, Carrasco I, Barreiro P, Peña JM, de Mendoza C. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opin Drug Metab Toxicol 2017;13:1015-22. [PMID: 28753040 DOI: 10.1080/17425255.2017.1359254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
253 Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL. Real life experiences in HCV management in 2018. Expert Rev Anti Infect Ther 2019;17:117-28. [PMID: 30582384 DOI: 10.1080/14787210.2019.1563755] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
254 Brandão R, Marcelino R, Gonçalves F, Diogo I, Carvalho A, Cabanas J, Costa I, Brogueira P, Ventura F, Miranda A, Mansinho K, Gomes P. Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. Viruses 2018;10:E223. [PMID: 29701642 DOI: 10.3390/v10050223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
255 Soria ME, García-Crespo C, Martínez-González B, Vázquez-Sirvent L, Lobo-Vega R, de Ávila AI, Gallego I, Chen Q, García-Cehic D, Llorens-Revull M, Briones C, Gómez J, Ferrer-Orta C, Verdaguer N, Gregori J, Rodríguez-Frías F, Buti M, Esteban JI, Domingo E, Quer J, Perales C. Amino Acid Substitutions Associated with Treatment Failure for Hepatitis C Virus Infection. J Clin Microbiol 2020;58:e01985-20. [PMID: 32999010 DOI: 10.1128/JCM.01985-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
256 Ashraf MU, Iman K, Khalid MF, Salman HM, Shafi T, Rafi M, Javaid N, Hussain R, Ahmad F, Shahzad-Ul-Hussan S, Mirza S, Shafiq M, Afzal S, Hamera S, Anwar S, Qazi R, Idrees M, Qureshi SA, Chaudhary SU. Evolution of efficacious pangenotypic hepatitis C virus therapies. Med Res Rev 2019;39:1091-136. [PMID: 30506705 DOI: 10.1002/med.21554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
257 Parlati L, Pol S. Direct acting antivirals failure: cause and retreatment options. Expert Rev Gastroenterol Hepatol. 2018;12:1245-1250. [PMID: 30791789 DOI: 10.1080/17474124.2018.1541237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
258 Ramirez S, Bukh J. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. Antiviral Res 2018;158:264-87. [PMID: 30059723 DOI: 10.1016/j.antiviral.2018.07.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
259 Scagnolari C, Turriziani O, Monteleone K, Pierangeli A, Antonelli G. Consolidation of molecular testing in clinical virology. Expert Rev Anti Infect Ther 2017;15:387-400. [PMID: 28002969 DOI: 10.1080/14787210.2017.1271711] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
260 Maasoumy B, Vermehren J. Diagnostics in hepatitis C: The end of response-guided therapy? J Hepatol 2016;65:S67-81. [PMID: 27641989 DOI: 10.1016/j.jhep.2016.07.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
261 Maan R, van der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res 2016;5:F1000 Faculty Rev-367. [PMID: 27006761 DOI: 10.12688/f1000research.7399.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
262 Kileng H, Kjellin M, Akaberi D, Bergfors A, Duberg AS, Wesslén L, Danielsson A, Gangsøy Kristiansen M, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy. Scand J Gastroenterol 2018;53:1347-53. [PMID: 30394152 DOI: 10.1080/00365521.2018.1511824] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
263 Miuma S, Miyaaki H, Miyazoe Y, Suehiro T, Sasaki R, Shibata H, Taura N, Nakao K. Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases. Transplant Proc 2018;50:222-5. [PMID: 29407313 DOI: 10.1016/j.transproceed.2017.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
264 Ramirez S, Fernandez-Antunez C, Mikkelsen LS, Pedersen J, Li YP, Bukh J. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c. Antimicrob Agents Chemother 2020;64:e01888-19. [PMID: 31818814 DOI: 10.1128/AAC.01888-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
265 Chaiwong S, Sistayanarain A. Characterization of partial NS5B region among hepatitis C virus genotype 6 subtypes isolated from Thai blood donors. J Med Virol 2016;88:1785-90. [PMID: 27018495 DOI: 10.1002/jmv.24536] [Reference Citation Analysis]
266 da Silva DL, Nunes HM, Freitas PEB. Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Pará/Brazil. Virus Res 2021;292:198251. [PMID: 33259871 DOI: 10.1016/j.virusres.2020.198251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
267 Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059 [PMID: 27672299 DOI: 10.3748/wjg.v22.i35.8050] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
268 Akiyama MJ, Riback L, Reeves JD, Lie YS, Agyemang L, Norton BL, Arnsten JH, Litwin AH. Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens. Open Forum Infect Dis 2021;8:ofab474. [PMID: 34692891 DOI: 10.1093/ofid/ofab474] [Reference Citation Analysis]
269 de Leuw P, Stephan C. Protease inhibitor therapy for hepatitis C virus-infection. Expert Opin Pharmacother 2018;19:577-87. [PMID: 29595065 DOI: 10.1080/14656566.2018.1454428] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
270 Murai K, Shimakami T, Welsch C, Shirasaki T, Liu F, Kitabayashi J, Tanaka S, Funaki M, Omura H, Nishikawa T, Sumiyadorj A, Honda M, Kaneko S. Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus. Antimicrob Agents Chemother 2018;62:e02601-17. [PMID: 29661883 DOI: 10.1128/AAC.02601-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
271 Wu R, Geng D, Chi X, Wang X, Gao X, Xu H, Shi Y, Guan Y, Wang Y, Jin J, Ding Y, Niu J. Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide. Infect Drug Resist. 2019;12:2987-3015. [PMID: 31571951 DOI: 10.2147/idr.s218584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
272 Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens. J Med Virol 2018;91:102-6. [DOI: 10.1002/jmv.25278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
273 Zeuzem S. Treatment Options in Hepatitis C. Dtsch Arztebl Int 2017;114:11-21. [PMID: 28143635 DOI: 10.3238/arztebl.2017.0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
274 Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514-528. [PMID: 28105744 DOI: 10.1111/liv.13327] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
275 Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Antimicrob Agents Chemother 2016;60:3563-78. [PMID: 27021330 DOI: 10.1128/AAC.02929-15] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
276 Fadl N, Salem TZ. Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes. Rev Med Virol 2020;30:e2120. [PMID: 32478480 DOI: 10.1002/rmv.2120] [Reference Citation Analysis]
277 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
278 Douam F, Ding Q, Ploss A. Recent advances in understanding hepatitis C. F1000Res. 2016;5:pii: F1000. [PMID: 26918166 DOI: 10.12688/f1000research.7354.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
279 Fahnøe U, Pedersen MS, Sølund C, Ernst A, Krarup HB, Røge BT, Christensen PB, Laursen AL, Gerstoft J, Thielsen P, Madsen LG, Pedersen AG, Schønning K, Weis N, Bukh J. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome. J Viral Hepat 2021;28:302-16. [PMID: 33131178 DOI: 10.1111/jvh.13430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
280 Abdel-Hameed EA, Rouster SD, Boyce CL, Zhang X, Biesiada J, Medvedovic M, Sherman KE. Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients. Dig Dis Sci 2018;63:645-52. [PMID: 29330726 DOI: 10.1007/s10620-017-4895-1] [Reference Citation Analysis]
281 Walker A, Ennker KS, Kaiser R, Lübke N, Timm J. A pan-genotypic Hepatitis C Virus NS5A amplification method for reliable genotyping and resistance testing. J Clin Virol 2019;113:8-13. [PMID: 30771598 DOI: 10.1016/j.jcv.2019.01.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Bagaglio S, Uberti-Foppa C, Olgiati A, Messina E, Hasson H, Ferri C, Morsica G. Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates. Virol J 2018;15:144. [PMID: 30227876 DOI: 10.1186/s12985-018-1054-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
283 Arends J, Kracht P, Hoepelman A. Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clinical Microbiology and Infection 2016;22:846-52. [DOI: 10.1016/j.cmi.2016.05.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
284 El-Khayat H, Kamal EM, Mahmoud H, Gomaa A, Ebeid B, Sameh Y, Hasseb A, El Raziky M, El Serafy M, Doss W, Esmat G, Fouad Y, Attia D. Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens. Eur J Gastroenterol Hepatol 2020;32:440-6. [PMID: 31688311 DOI: 10.1097/MEG.0000000000001581] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
285 Stanciu C, Trifan A, Muzica C, Sfarti C. Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opin Pharmacother 2019;20:379-84. [PMID: 30576256 DOI: 10.1080/14656566.2018.1560424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]